Prevalence and risk factors of dyslipidemia among male industrial workers in India

Wankhade, Pratibha Suresh; Pedhambkar, R. B.; Pagare, Rajani Satish

doi:10.18203/2394-6040.ijcmph20181217

Cited by 11 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present finding is consistent with the results reported in Palestine (66.4%) [18] and South Africa (67.3%) [19]. However, the prevalence of dyslipidemia in this study is higher than the previous findings reported in Eastern Ethiopia (34.8%) [11], Africa PLOS ONE (25.5%) [9], China (32.2%) [20], Iran (30.0%) [21], India (50.7%) [22], and Uganda (63.3%) [23]. Contrary to this, the prevalence is lower than previous studies reported in Lithuania (89.7%) [24], South Africa (85.0%) [25], India (78.4%) [26] and Poland (77.2%) [27].…”

Section: Plos Onesupporting

confidence: 91%

See 1 more Smart Citation

Prevalence of dyslipidemia and associated risk factors among adult residents of Mekelle City, Northern Ethiopia

et al. 2021

View full text Add to dashboard Cite

Introduction Dyslipidemia is a major risk factor for cardiovascular diseases (CVD). The prevalence of dyslipidemia is not known among Ethiopian adults. The prevalence is expected to rise due to the socio-economic development accompanied by lifestyle changes. This study was conducted to estimate the prevalence of dyslipidemia and associated risk factors among adult residents of Mekelle City. Methods A community-based cross-sectional study was conducted among 321 randomly selected subjects. Data were collected on sociodemographic, anthropometric, lifestyle, and clinical characteristics of the participants using the WHO STEPS survey instrument. Data were analyzed using SPSS software version 24.0. Student’s t-test and Pearson’s Chi-square test were used to assessing the interrelationship between each factor and outcome variables. Bivariate and multivariable logistic regression analysis were used to identify risk factors associated with dyslipidemia. All statistical significance was considered at p ≤0.05. Results The prevalence of dyslipidemia in this study was 66.7%. The prevalence of high low-density lipoprotein cholesterol (LDL-C), elevated triglyceride, elevated total cholesterol, and low high-density lipoprotein cholesterol (HDL-C) was 49.5%, 40.2%, 30.8%, and 16.5%, respectively. Being above 64 years (aOR: 2.196, 95% CI: 1.183–4.078) and 40–64 years old (aOR: 2.196, 95% CI: 1.183–4.078), overweight (aOR: 2.50, 95% CI: 1.314–4.756) and obesity (aOR: 15.489, 95% CI: 3.525–68.070), walking <150 minutes per week (aOR: 1.722, 95% CI: 1.004–2.953), raised fasting blood glucose (FBG) (aOR: 4.804, 95% CI: 1.925–11.988), and medium socio-economic status (aOR: 2.017, 95% CI: 1.044–3.899) were identified as significant predictors of dyslipidemia. Conclusions The finding of this study indicated that the prevalence of dyslipidemia is unacceptably high among adult residents of Mekelle City, which underlines an urgent need for early detection and public health interventions through the integrated involvement of public, governmental, and non-governmental organizations.

show abstract

Section: Plos Onesupporting

confidence: 91%

“…Africa (18.5%) [9]. Unlike many previous studies [22,30,38,[42][43][44][45], low HDL-C is the least prevalent component of dyslipidemia in this study. Advanced age, higher BMI, waking less than 150 minutes per week, raised FBG, and medium socio-economic status were significantly associated with a higher risk of dyslipidemia.…”

Section: Plos Onecontrasting

confidence: 65%

Prevalence of dyslipidemia and associated risk factors among adult residents of Mekelle City, Northern Ethiopia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The prevalence of reduced HDL-C in this study, 50.7% is higher than the findings reported in Togo, 16.4% [ 5 ], Mekelle, 16.5% [ 18 ], China, 20.8% [ 1 ], and Durame, southern Ethiopia, 41.9% [ 15 ]. Whereas, it is lower than the findings from India, 62% [ 22 ], and Ethiopia, 68.7% [ 9 ]. These variations might be due to differences in cut-off values, distribution of risk factors, study setting, and socio-economic status of the participants.…”

Section: Discussioncontrasting

confidence: 58%

“…The overall prevalence of dyslipidemia reported in this study is consistent with the findings reported in Mekelle, 66.7% [ 18 ], and Durame, southern Ethiopia, 65.6% [ 15 ]. However, the prevalence is higher than the findings reported in Africa, 29.7% [ 4 ], Eastern Ethiopia, 34.8% [ 6 ], China, 43.3% [ 1 ], India, 50.7% [ 22 ], Iran, 51.8% [ 23 ], Sao Paulo, 59.74% [ 24 ], Nigeria, 60% [ 25 ], and Togo, 60.3% [ 5 ]. The reason for the high prevalence in this study might be attributed to differences in sample sizes, study setting, study population, socio-economic status, and lifestyle of the study participants [ 23 ].…”

Section: Discussionmentioning

confidence: 79%

Factors associated with dyslipidemia and its prevalence among Awash wine factory employees, Addis Ababa, Ethiopia: a cross-sectional study

Angassa

Solomon

Seid

2022

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Dyslipidemia is a highly prevalent and modifiable risk factor for atherosclerotic cardiovascular diseases. Though the problem is significant in Ethiopia, available data in this regard is very poor among alcoholic beverage industrial workers. This study aimed to assess factors associated with dyslipidemia and its prevalence among Awash wine factory employees in Addis Ababa, Ethiopia. Methods A cross-sectional study was conducted among 335 randomly selected employees of Awash wine factory, Addis Ababa, Ethiopia from January to February 2021. Data was collected by a face-to-face interview technique using the WHO STEPwise approach. Data were entered and analyzed using Epi Info 7 and SPSS version 26, respectively. Both bivariable and multivariable logistic regression analyses were performed to identify factors associated with dyslipidemia. All statistical tests were declared significant at p-value < 0.05. Results The overall prevalence of dyslipidemia was 67.8% (95% CI 62.5–72.7%). Elevated total cholesterol, elevated triglycerides, reduced high-density lipoprotein, and elevated low-density lipoprotein was found in 25.4%, 33.4%, 50.7%, and 21.5% of participants, respectively. Dyslipidemia was significantly associated with age group 30–39 years (AOR = 2.51; 95% CI 1.16–5.44, p = 0.019), ≥ 40 years (AOR = 6.45; 95% CI 2.01–20.71, p = 0.002), current alcohol consumption (AOR = 3.37; 95% CI 1.70–6.66, p < 0.001), eating vegetables < 2 days per week (AOR = 2.89; 95% CI 1.54–5.43, p = 0.001), sitting duration of > 4 h per day (AOR = 1.96; 95% CI 1.03–3.74, p = 0.041), and raised waist circumference (AOR = 4.56; 95% CI 2.07–10.08, p < 0.001). Conclusions High prevalence of dyslipidemia was found among Awash wine factory employees in Addis Ababa. Periodic screening of high-risk groups along with effective health promotion and education which encourages a healthy lifestyle is essential.

show abstract

“…It is quite common that atherosclerosis and blood vessel disease may develop even before diabetes is diagnosed. 11,12 The treatment of Rosuvastatin and Fenofibrates has altered the Serum Total Cholesterol, LDL, and TGL and subsequent gradual increase in HDL (Table 9). Lowering LDL has become a primary goal in cardiovascular prevention and commonly estimated from quantitative measurements of total and HDL-cholesterol and plasma triglycerides (TG) using the empirical relationship of Friedewald et al And also, LDL has been associated with the development of plaque deposits on artery walls, which narrow the passage and restrict blood flow.…”

Section: Resultsmentioning

confidence: 99%

Rosuvastatin plus fenofibrate in diabetic dyslipidemia: a hospital record based study

Gopal

Meganathan

Vithiavathi

et al. 2018

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Cardiovascular diseases (CVD) are the leading cause of death throughout world population each and every year. Focus on dyslipidemia management is urgently required in India to halt the rising tide of CVD. The purpose of diabetic dyslipidemia study is a record based one, to find out the effect of Rosuvastatin plus Fenofibrate, in adult Type 2 diabetes with dyslipidemia, with high TGL/HDL ratio in Lipid profiles, in a tertiary care hospital in the Union territory of Puducherry.Methods: There were 101 patients hospital records were analysed in which male were 45 and females were 56. The various biochemical parameters like serum Total Cholesterol, HDL, LDL, TGL, Non-HDL, TCL/HDL Ratio and TGL/HDL ratio reports were collected before and after 12-weeks of Rosuvastatin 10 mg with Fenofibrate 145 mg combination, for the treatment period once daily for their lipid-lowering therapy.Results: The combination therapies of Rosuvastatin plus Fenofibrate were safe and feasible to achieve more TG goal and proved that has predominately decreased the elevated lipid profiles from the medical resources of our record based study. The use of combination medications of rosuvastatin (10mg) plus Fenofibrate (145mg) is often needed to effectively treat the lipid triad, by the potency of rosuvastatin to lower LDL-C and Fenofibrates effectiveness in lowering TG in treating mixed diabetic dyslipidemia.Conclusions: After Rosuvastatin (10mg) plus Fenofibrate (145mg), the lipid profile data proved that the importance of TGL/HDL ratio apart from the TCL/HDL ratio, for good lipid control in diabetic dyslipidemic patients.

show abstract

Prevalence and risk factors of dyslipidemia among male industrial workers in India

Cited by 11 publications

References 18 publications

Prevalence of dyslipidemia and associated risk factors among adult residents of Mekelle City, Northern Ethiopia

Prevalence of dyslipidemia and associated risk factors among adult residents of Mekelle City, Northern Ethiopia

Factors associated with dyslipidemia and its prevalence among Awash wine factory employees, Addis Ababa, Ethiopia: a cross-sectional study

Rosuvastatin plus fenofibrate in diabetic dyslipidemia: a hospital record based study

Contact Info

Product

Resources

About